Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Rev Med Interne ; 41(4): 284-288, 2020 Apr.
Article in French | MEDLINE | ID: mdl-31983550

ABSTRACT

INTRODUCTION: Immune Checkpoint Inhibitor (ICI) therapy is now a standard of care in numerous cancers with very promising results. Nevertheless, adverse events, and especially immune-related adverse events (irAEs) not reported during clinical trials, are emerging and can be life-threatening. OBSERVATION: We report here a teachable case of a 80 year-old man, of third-degree atrioventricular block consecutive to myocarditis associated with the administration of nivolumab (anti-PD1) monotherapy. CONCLUSION: Myocarditis occurring during ICI treatment is a rare but potentially lethal event. Daily serum troponin level seems to predict ICI-related myocarditis but interpretation could be difficult in the context of associated myositis. Echocardiography and cardiac MRI are also useful but can remain negative. Electrocardiogram is a cornerstone of myocarditis diagnosis. In case of cardiac involvement, continuous heart rhythm monitoring should be performed in addition to the administration of high-dose corticosteroids therapy and the cessation of ICI therapy. Add-on treatments should be discussed with a well-trained multidisciplinary team.


Subject(s)
Atrioventricular Block/chemically induced , Immune Checkpoint Inhibitors/adverse effects , Myocarditis/chemically induced , Nivolumab/adverse effects , Aged, 80 and over , Antineoplastic Agents, Immunological/adverse effects , Antineoplastic Agents, Immunological/therapeutic use , Atrioventricular Block/complications , Atrioventricular Block/pathology , Carcinoma, Squamous Cell/complications , Carcinoma, Squamous Cell/drug therapy , Diabetes Mellitus, Type 2/complications , Humans , Immune Checkpoint Inhibitors/therapeutic use , Immunotherapy/adverse effects , Lung Neoplasms/complications , Lung Neoplasms/drug therapy , Male , Myocarditis/complications , Myocarditis/pathology , Nivolumab/therapeutic use , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Programmed Cell Death 1 Receptor/immunology
2.
Rev Mal Respir ; 34(9): 976-990, 2017 Nov.
Article in French | MEDLINE | ID: mdl-29150179

ABSTRACT

BACKGROUND: The aim of ESCAP-2011-CPHG, promoted by the French College of General Hospital Respiratory Physicians, was to describe therapeutic strategies in lung cancer in the first 2 years after diagnosis, in a real-life setting. This article focuses on patients undergoing surgical management of a non-small cell lung cancer (NSCLC). METHODS: A prospective multicentre study was conducted in 53 French general hospitals. For each patient with lung cancer diagnosed in 2010, a standardised form was completed following each change in treatment strategy up to 2 years after diagnosis. RESULTS: Overall, 3418 of the 3943 included patients had NSCLC. 741 patients (21.7%) underwent curative surgery (stage 0-II, IIIA, IIIB, and IV: 65%, 27%, 3% and 5%, respectively). The therapeutic strategy changed less often in surgical than non-surgical patients and average follow-up time was longer: 23.3 months (SD: 9.3) versus 10.4 months (SD: 9.5) for non-surgical patients. Among patients with a surgical first strategy (92.6% of surgical patients as a whole), 56.9% did not receive any other treatment, 34.7% received chemotherapy, 5.9% radio-chemotherapy, 2.6% radiotherapy. At the end of follow-up, 55.8% were still alive without any other strategy, 13.1% had died, and 31.1% had received at least one more strategy. Among patients with a surgical second strategy, 63% had received chemotherapy alone during the first strategy. CONCLUSIONS: ESCAP -2011- CPHG assessed everyday professional practice in the surgical management of NSCLC in general hospitals. It pointed out the discrepancies between current guidelines and the therapeutic strategies applied in real life conditions.


Subject(s)
Carcinoma, Non-Small-Cell Lung/surgery , Carcinoma, Non-Small-Cell Lung/therapy , Lung Neoplasms/surgery , Lung Neoplasms/therapy , Practice Patterns, Physicians' , Pulmonary Medicine/methods , Adult , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/diagnosis , Carcinoma, Non-Small-Cell Lung/epidemiology , Cohort Studies , Female , Follow-Up Studies , France/epidemiology , Hospitals, General/organization & administration , Hospitals, General/statistics & numerical data , Humans , Lung Neoplasms/diagnosis , Lung Neoplasms/epidemiology , Male , Middle Aged , Pneumonectomy/methods , Pneumonectomy/statistics & numerical data , Practice Patterns, Physicians'/statistics & numerical data , Pulmonary Medicine/organization & administration , Societies, Medical/organization & administration , Societies, Medical/standards , Workforce
3.
Rev Pneumol Clin ; 59(3): 161-5, 2003 Jun.
Article in French | MEDLINE | ID: mdl-13130203

ABSTRACT

Gastrointestinal metastasis from lung cancer is exceptional and generally asymptomatic. Other secondary localizations are often present. Metastastic dissemination may involve any portion of the gastrointestinal tract. Clinical expression is variable: dysphagia, anemia, bowel obstruction, peritonitis. Surgical treatment may be indicated in selected patients. We describe the cases of two patients who developed obstruction of the small bowel due to metastases from squamous-cell lung cancer. Bowel obstruction was in the inaugural sign in the first patient. Mesenteric metastasis was associated in the second patient.


Subject(s)
Carcinoma, Non-Small-Cell Lung/secondary , Carcinoma, Squamous Cell/secondary , Intestinal Neoplasms/secondary , Intestinal Obstruction/etiology , Lung Neoplasms/pathology , Carcinoma, Non-Small-Cell Lung/complications , Carcinoma, Squamous Cell/complications , Humans , Intestinal Neoplasms/complications , Male , Middle Aged
4.
Presse Med ; 32(22): 1028-30, 2003 Jun 21.
Article in French | MEDLINE | ID: mdl-12876519

ABSTRACT

INTRODUCTION: Vibrio vulnificus proliferates during the summer in salt water where it infects the crustaceans. Expression of its pathogenicity depends on the underlying condition and mode of contamination. OBSERVATION: A 65 year-old man presented with a Vibrio vulnificus septicaemia of cutaneous origin, transmitted when he cut himself with a crawfish. The severity of the infection was enhanced by severe immuno-depression and haemochromatosis. The infection regressed with appropriate antibiotherapy. COMMENTS: Severe V. vulnificus infections are rare. Depending on the underlying condition and mode of contamination, one can distinguish between benign gastro-enteritis, local occasionally devastating infections and usually fatal septicaemia. CONCLUSION: Even the most severe forms of V. vulnificus infections may be cured with early and well adapted anti-infectious treatment.


Subject(s)
Decapoda , Lacerations/complications , Sepsis/etiology , Vibrio Infections/etiology , Vibrio vulnificus/pathogenicity , Aged , Anti-Bacterial Agents/therapeutic use , Humans , Lacerations/microbiology , Male , Sepsis/drug therapy , Sepsis/pathology , Severity of Illness Index , Vibrio Infections/drug therapy , Vibrio Infections/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...